Value Sense
CMPS
COMPASS Pathways plc (CMPS)
Last Price$3.7(6.6%)
Market Cap$253.4M
LTM EBITDA
($148.1M)
YoY Growth
+21.7%
3Y CAGR
+36.3%
5Y CAGR
+65.1%
Stock quality & Intrinsic value
5/10
30.5% overvalued
CMPS
is (30.5%) overvalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

COMPASS Pathways plc EBITDA

Annual
Quarterly
LTM
Crunching data... Almost there!
Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23
EBITDA
($10.5M)
($18.4M)
($47.0M)
($83.2M)
($110.4M)
($123.8M)
CMPS
Key metrics and insights to make informed decisions.
View full analysis
Overvalued or undervalued?
Check the intrinsic value for CMPS and see if it's the right time to invest.
Dive in

COMPASS Pathways plc (CMPS) EBITDA comparison analysis

General

LTM EBITDA

Growth

Company name

YoY growth

3Y CAGR

5Y CAGR

COMPASS Pathways plc logo
COMPASS Pathways plcCMPS
($148.1M)
21.7%
36.3%
65.1%
Median Peer Set
$1,702.2M
14.9%
5.6%
5.5%
HCA Healthcare, Inc. logo
HCA Healthcare, Inc.HCA
$14.1B
11.0%
3.9%
7.4%
Tenet Healthcare Corporation logo
Tenet Healthcare CorporationTHC
$4,299.0M
19.2%
9.9%
9.5%
Fresenius Medical Care AG & Co. KGaA logo
Fresenius Medical Care AG & Co. KGaAFMS
$2,804.4M
(20.0%)
(9.9%)
(8.0%)
DaVita Inc. logo
DaVita Inc.DVA
$2,745.1M
18.1%
3.8%
3.0%
Universal Health Services, Inc. logo
Universal Health Services, Inc.UHS
$2,271.4M
30.3%
5.6%
4.7%
Encompass Health Corporation logo
Encompass Health CorporationEHC
$1,132.9M
11.6%
5.6%
3.8%
Acadia Healthcare Company, Inc. logo
Acadia Healthcare Company, Inc.ACHC
$609.8M
163.4%
11.1%
4.4%
The Ensign Group, Inc. logo
The Ensign Group, Inc.ENSG
$437.4M
23.8%
10.9%
16.9%
Chemed Corporation logo
Chemed CorporationCHE
$423.0M
2.1%
0.9%
6.3%
Option Care Health, Inc. logo
Option Care Health, Inc.OPCH
$371.5M
(22.4%)
13.2%
36.4%

CMPS key stats

USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23
Revenue
% growth
0.0
0.0%
0.0
0.0%
0.0
0.0%
0.0
0.0%
0.0
0.0%
0.0
0.0%
Cost of Goods Sold (COGS)0.00.10.10.20.30.2
Gross Profit
% margin
0.0
0.0%
(0.1)
0.0%
(0.1)
0.0%
(0.2)
0.0%
(0.3)
0.0%
(0.2)
0.0%
Operating Expenses10.518.547.173.696.0136.9
Research & Development Expenses (R&D)8.912.623.444.065.187.5
Selling, General & Administrative Expenses (SG&A)3.68.628.039.245.449.4
Operating Income
% margin
(12.5)
0.0%
(21.2)
0.0%
(51.4)
0.0%
(83.2)
0.0%
(110.4)
0.0%
(136.9)
0.0%
Interest Income0.00.00.00.00.00.0
Interest Expense0.00.00.00.00.02.2
Pre-tax Income(13.2)(19.6)(60.3)(71.5)(91.1)(117.7)
Income Tax
% effective tax rate
(0.7)
5.4%
0.0
(0.1%)
0.0
(0.1%)
0.2
(0.3%)
0.4
(0.4%)
0.8
(0.7%)
Net Income
% margin
(13.2)
0.0%
(19.6)
0.0%
(60.3)
0.0%
(71.7)
0.0%
(91.5)
0.0%
(118.5)
0.0%
EPS(0.00)(0.90)(1.68)(1.79)(2.16)(2.32)
Diluted EPS(0.00)(0.90)(1.68)(1.79)(2.16)(2.32)
EBITDA
% margin
(10.5)
0.0%
(18.4)
0.0%
(47.0)
0.0%
(83.2)
0.0%
(110.4)
0.0%
(123.8)
0.0%

Discover more Stock Ideas

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks

Undervalued growth stocks

Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
More ideas -->

FAQ

1) What is COMPASS Pathways plc's EBITDA?

As of today, COMPASS Pathways plc's last 12-month EBITDA is ($148.1M), based on the financial report for Sep 30, 2024 (Q3’2024).

2) What is COMPASS Pathways plc's EBITDA growth rate?

Over the last year, COMPASS Pathways plc's EBITDA growth was 21.7%. The average annual EBITDA growth rates for COMPASS Pathways plc have been 42.2% over the past three years, 65.1% over the past five years.

3) Is COMPASS Pathways plc's EBITDA growth rate Good?

Over the last year, COMPASS Pathways plc's EBITDA growth was 21.7%, which is higher than industry growth of 0.5%. It indicates that COMPASS Pathways plc's EBITDA growth is Good.

4) How does COMPASS Pathways plc's EBITDA growth rate compare to its peers?

Over the last year, COMPASS Pathways plc's EBITDA growth was 21.7%, which is lower than peer median growth of 23.4%. The list of peers includes HCA, THC, FMS, DVA, UHS, EHC, ACHC, ENSG, CHE, OPCH etc.